Palisades Therapeutics Unveils Breakthrough Multi-Mechanistic Data for PT150 and PT157 in Resistant Cancers

Dual AR/GR Antagonism, Metabolic Reprogramming, and Lysosomal Bypass Position PT150 and PT157 as Best-in-Class Oncology Candidates

CLIFFSIDE PARK, NJ, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Pop Test Oncology LLC dba Palisades Therapeutics, a clinical-stage biopharmaceutical company, today released compelling preclinical data for clinical-stage PT150 and its early-stage dimer PT157, demonstrating their superiority over existing glucocorticoid receptor (GR) antagonists like Relacorilant™.

Pop Test/Palisades Therapeutics

Key Differentiators: PT150/PT157 vs. Relacorilant ™ according to Perplexity ai

Parameter	PT150/PT157	Relacorilant ™
Mechanism	Dual AR/GR blockade + epigenetic/metabolic modulation + lysosomal bypass	GR antagonism only
Target Pathways	- Epigenetic (*H2AFV*↑, *SMARCA4*↓) - Metabolic (*ACADL*↓, *SDHA*↑) - Stromal (*ACTA2*↓) - Lysosomal (*RAB9A*↓)	GR-SGK1/DUSP1 pathway only
Preclinical Efficacy	- **55.3% TGI** in taxane-resistant breast/ovarian cancer - **100% survival** in PDX ovarian models - **IC50 advantage** in resistant pancreatic/liver cancer cells - **ZTX® PREDICT in Vivo Platform Validation**: Synergy with standard care in prostate models	60.5% TGI (pancreatic models)
Combination Potential	Synergizes with taxanes (Abraxane/Cabazitaxel), PARP inhibitors, HSP90 modulators	Limited to nab-paclitaxel
Biomarkers	*RAB9A*↓, *SMARCA4*↓, *KALRN*↓, *OVOL2*↑	*SGK1*↓, *DUSP1*↓
Market Potential	Targets AR+/GR+/ARID1A-mutant tumors across **$8B+ indications**	$2B niche (GR-high ovarian cancer)

Key Differentiators: PT150 and PT157 vs. Relacorilant

These findings position PT150 and PT157 as transformative therapies for taxane-resistant and AR/GR-driven cancers, including pancreatic, ovarian, liver, prostate, and colorectal malignancies.

Breakthrough Mechanistic Insights

• Dual AR/GR Targeting: Disrupts survival pathways in AR+/GR+ tumors (~30% of pancreatic, ovarian, and prostate cancers).

• Epigenetic Modulation: Reverses PARP resistance (H2AFV□) induces synthetic lethality in ARID1A-mutant tumors (SMARCA4□).

• Metabolic & Stromal Targeting: ACADL disrupts fatty acid oxidation; ACTA2 reduces fibrosis for improved drug delivery.

• Lysosomal Resistance Bypass: RAB9A prevents taxane sequestration, enhancing chemotherapy efficacy.

• ZTX® PREDICT Platform Validation: Rapid 5-day in vivo testing identifies responders/non-responders, with high prediction of patient treatment outcome, accelerating preclinical-to-clinical translation.

Strategic Next Steps

• Global Partnerships: Leverage data for potential collaborations with leading companies such as Pfizer, Gilead, Bristol-Myers Squibb, and Astellas.

Compelling Preclinical Data Across Multiple Cancers

Cancer Type (Site)	Model	Treatment	Key Findings
Pancreatic Cancer (Georgetown University)	n-PTX-resistant PDAC	PT150/PT157 + nab-paclitaxel	Overcomes resistance (IC50 advantage); *RAB9A↓, ACTA2↓, SMARCA4↓, H2AFV↑*
Ovarian Cancer (TD2/TGEN, Sai Life Science)	PDX models	PT157 + Enzalutamide	100% survival at 60 days; robust synergy in AR+/GR+ subtypes
Triple-Negative Breast Cancer (TD2/TGEN)	Xenograft	PT150 + Paclitaxel	55.3% tumor growth inhibition (TGI); 2.7x tumor volume reduction
Liver Cancer (HCC/CHC) (Kurume University-Japan)	11 HCC & 2 CHC cell lines	PT150/PT157	Cell growth suppressed in 10/11 (PT150) and 11/11 (PT157) lines; IC50 5.1–19.8 μM
Prostate Cancer (Mount Sinai & BioReperia)	Zebrafish Tumor Xenograft	PT150/PT157 + Standard Care, Enzalutamide	Synergistic inhibition of metastasis; rapid 5-day efficacy testing
Prostate Cancer (Mount Sinai & Sai Life Science)	CRPC cell lines	PT150/PT157 + Abiraterone/ARN509/ Enzalutamide	6.8x boost in cell death (PT150); PT157 2–4x more potent than AR antagonists

Compelling Preclinical Data Across Multiple Cancers

Why This Matters: PT150 and PT157's multi-target approach offers hope for durable remissions in resistant pancreatic, ovarian, liver, and prostate cancers.

About Palisades Therapeutics

Palisades Therapeutics is a lean, innovation-driven biotech leveraging a global network of 75+ experts to accelerate transformative oncology therapies. Learn more at www.palisadestherapeutics.com

Disclaimer:
Relacorilant™ is a trademark and drug owned by Corcept Therapeutics. Palisades Therapeutics and its affiliates have no relationship, affiliation, or endorsement from Corcept Therapeutics. Any comparative data regarding Relacorilant™ referenced in this press release, prepared through Perplexity. ai were determined through publicly available publications and are not based on direct collaboration or proprietary information from Corcept Therapeutics.

Forward-looking statements: This release contains projections based on preclinical data. Clinical outcomes may differ.

#Pfizer, #Gilead, #BMS, #Astellas, #Oncology, #CancerResearch

Randi Altschul
Pop Test Oncology/Palisades Therapeutics
+1 201-943-3770
email us here
Visit us on social media:
LinkedIn